Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor ...

When hormone therapy stops working, the cancer is said to be “castration resistant.” On average, it takes about two years for prostate cancer to become resistant to hormone therapy ...

Research at City of Hope reveals how common white button mushrooms might enhance prostate cancer treatment through surprising ...

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.Da3GqCks.js ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...